Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + Pemetrexed in First-line Advanced Non-squamous NSCLC
NCT00871403Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of pazopanib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: Progression-free Survival up to 85 weeks. Started Jul 2009; status: completed.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00871403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871403.